Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Q702 in Hematologic Malignancies
NCT06712810Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Aug 2025
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adrixetinib in histiocytic sarcoma (HS), malignant histiocytosis (MH), peripheral T-cell lymphoma (PTCL) and 17 more, sponsored by Mayo Clinic. Primary endpoints: Incidence of Dose Limiting Toxicity up to 3 years and Overall Response Rate up to 3 years. Started Aug 2025; status: recruiting.
02
Drugs
adrixetinib
03
Conditions
histiocytic sarcoma (HS)malignant histiocytosis (MH)peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT06712810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06712810.